PHOSPHODIESTERASE TYPE 5 INHIBITORS IN THE TREATMENT OF ERECTILE DYSFUNCTION: PAST, PRESENT AND FUTURE
- Authors: Gamidov S.I1, Ovchinnikov R.I1, Popova A.Y.1, Izhbaev S.K.1
-
Affiliations:
- V.I. Kulakov Research Center for Obstetrics, Gynecology and Perinatology of Minzdrav of Russia
- Issue: No 1 (2017)
- Pages: 103-107
- Section: Articles
- URL: https://journals.eco-vector.com/1728-2985/article/view/286771
- DOI: https://doi.org/10.18565/urol.2017.l.103-107
- ID: 286771
Cite item
Abstract
Full Text
About the authors
S. I Gamidov
V.I. Kulakov Research Center for Obstetrics, Gynecology and Perinatology of Minzdrav of Russia
Email: s_gamidov@oparina4.ru
Dr.Med.Sci., Head of the Department of Andrology and Urology
R. I Ovchinnikov
V.I. Kulakov Research Center for Obstetrics, Gynecology and Perinatology of Minzdrav of Russia
Email: r_ovchinnikov@oparina4.ru
PhD, Head of the Department of Andrology and Urology for Clinic
A. Yu Popova
V.I. Kulakov Research Center for Obstetrics, Gynecology and Perinatology of Minzdrav of Russia
Email: a_popova@oparina4.ru
PhD, SR at the Department of Andrology and Urology
S. Kh Izhbaev
V.I. Kulakov Research Center for Obstetrics, Gynecology and Perinatology of Minzdrav of Russia
Email: s_izhbaev@oparina4.ru
Urologist-Andrologist at the Department of Andrology and Urology
References
- NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence.JAMA. 1993;270:83-90.
- Feldman H.A., Goldstein I., Hatzjchristou D.G., Krane R.J., McKinlay J.B. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994;151:54-61.
- Jackson G., Gillies H., Osterloh I. Past, present, and future: a 7-year update of Viagra (sildenafil citrate). Int J Clin Pract 2005;59:680-91.
- Polinski J.M., Kesselheim A.S. Where cost, medical necessity, and morality meet: should US government insurance programs pay for erectile dysfunction drugs? Clin Pharmacol Ther. 2011;89:17-19.
- Melman A , Gingell J.C. The epidemiology and pathophysiology of erectile dysfunction. J Urol. 1999;161:5-11.
- Burnett A.L. Nitric oxide in the penis: physiology and pathology. J Urol. 1997;157:320-24.
- Jeremy J.Y., Ballard S.A., Naylor A.M., Miller M.A., Angelini G.D. Effects of sildenafil, a type-5 cGMP phosphodiesterase inhibitor, and papaverine on cyclic GMP and cyclic AMP levels in the rabbit corpus cavernosum in vitro. Br J Urol. 1997;79:958-963.
- Kotera J., Mochida H., Inoue H., Noto T., Fujishige K., Sasaki T., Kobayashi T., Kojima K., Yee S., Yamada Y., Kikkawa K., Omori K. Avanafil, a potent and highly selective phosphodiesterase-5 inhibitor for erectile dysfunction. J Urol. 2012;188:668-674.
- Boolell M., Allen M.J., Ballard S.A., Gepi-Attee S., Muirhead G.J., Naylor A.M., Osterloh I.H., Gingell C. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res. 1996;8:47-52.
- Goldstein I., Lue T.F., Padma-Nathan H., Rosen R.C., Steers W.D., Wicker P.A. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med. 1998;338:1397-1404.
- Boulton A.J., Selam J.L., Sweeney M., Ziegler D. Sildenafil citrate for the treatment of erectile dysfunction in men with Type II diabetes mellitus. Diabetologia. 2001;44:1296-1301.
- Meuleman E., Cuzin B., Opsomer R.J., Hartmann U., Bailey M.J., Maytom M.C., Smith M.D., Osterloh I.H. A dose-escalation study to assess the efficacy and safety of sildenafil citrate in men with erectile dysfunction. BJU Int. 2001;87:75-81.
- McCullough A.R., Barada J.H., Fawzy A., Guay A.T., Hatzichristou D. Achieving treatment optimization with sildenafil citrate (Viagra) in patients with erectile dysfunction. Urology. 2002;60:28-38.
- Goldstein I., Lue T.F., Padma-Nathan H., Rosen R.C., Steers W.D., Wicker P.A. Oral Sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N EngI J Med. 1998;338: 1397-1404.
- Камалов А.А., Осмоловский Б.Е., Охоботов Д.А., Ходырева Л.А., Тахирзаде Т.Б., Тахирзаде А.М., Геворкян А.Р. Комбинированное лечение больных с эректильной дисфункцией, страдающих расстройствами мочеиспускания, Урология. 2013;3:29-33
- Giuliano F., Jackson G., Montorsi F., Martin-Morales A., Raillard P. Safety of sildenafil citrate: review of 67 double-blind placebocontrolled trials and the postmarketing safety database. Int J Clin Pract. 2010;64(2):240-255.
- Инструкция по медицинскому применению Динамико.
- Klotz T., Sachse R., Heidrich A., Jockenhövel F., Rohde G., Wensing G., Horstmann R., Engelmann R. Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: a RigiScan and pharmacokinetic study. World J Urol. 2001;19:32-39.
- Hellstrom W.J., Gittelman M., Karlin G., Segerson T., Thibonnier M., Taylor T., Padma-Nathan H. Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, doubleblind, placebo-controlled trial. J Androl. 2002;23:763-771.
- Porst H., Rosen R., Padma-Nathan H., Goldstein I., Giuliano F., Ulbrich E., Bandel T. The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial. Int J Impot Res. 2001;13:192-199.
- Zumbé J., Porst H., Sommer F., Grohmann W., Beneke M., Ulbrich E. Comparable efficacy of once-daily versus on-demand vardenafil in men with mild-to-moderate erectile dysfunction: findings of the RESTORE study. Eur Urol. 2008;54:204-210.
- Rubio-Aurioles E., Porst H., Kim E.D., Montorsi F., Hackett G., Morales A.M., Stuckey B., Büttner H., West T.M., Huynh N.N., Lenero E., Burns P., Kopernicky V. A randomized open-label trial with a crossover comparison of sexual self-confidence and other treatment outcomes following tadalafil once a day vs. tadalafil or sildenafil on-demand in men with erectile dysfunction. J Sex Med. 2012;9:1418-1429.
- Padma-Nathan H., McMurray J.G., Pullman W.E., Whitaker J.S., Saoud J.B., Ferguson K.M., Rosen R.C. On-demand IC351 (Cialis) enhances erectile function in patients with erectile dysfunction. Int J Impot Res. 2001;13:2-9.
- Brock G.B., McMahon C.G., Chen K.K., Costigan T., Shen W., Watkins V., Anglin G., Whitaker S. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol. 2002;168:1332-1336.
- Goldfischer E.R., Kim E.D., Seftel A.D., Baygani S.K., Burns P.R. Impact of low testosterone on response to treatment with tadalafil 5 mg once daily for erectile dysfunction. Urology. 2014;83:1326-1333.
- Porst H., Oelke M., Goldfischer E.R., Cox D., Watts S., Dey D., Viktrup L. Efficacy and safety of tadalafil 5 mg once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: subgroup analyses of pooled data from 4 multinational, randomized, placebo-controlled clinical studies. Urology. 2013;82:667-673.
- Buvat J., Hatzichristou D., Boess F.G., Büttner H., Gehchan N., Henneges C., Porst H. Continuation and effectiveness of tadalafil once daily during a 6-month observational study in erectile dysfunction: the ED ATE study. Int J Clin Pract. 2014; 68:1087-99.
- Montague D.K., Jarow J.P., Broderick G.A., Dmochowski R.R., Heaton J.P., Lue T.F., Milbank A.J., Nehra A., Sharlip I.D.; Erectile Dysfunction Guideline Update Panel. Chapter 1: The management of erectile dysfunction: an AUA update. J Urol. 2005;174:230-39.
- Hatzimouratidis K., Amar E., Eardley I., Giuliano F., Hatzichristou D., Montorsi F., Vardi Y., Wespes E.; European Association of Urology. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol. 2010;57:804-814.
- Bai W.J., Li H.J., Dai Y.T., Huang Y.R., Liu J.H., Sorsaburu S., Ji C., Jin J.J., Wang X.F. An open-label, multicenter, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in Chinese men naïve to phosphodiesterase 5 inhibitor therapy. Asian J Androl. 2015;17:61-67.
- Shabsigh R., Seftel A.D., Rosen R.C., Porst H., Ahuja S., Deeley M.C., Garcia C.S., Giuliano F. Review of time of onset and duration of clinical efficacy of phosphodiesterase type 5 inhibitors in treatment of erectile dysfunction. Urology. 2006;68:689-696.
- Tsertsvadze A., Fink H.A., Yazdi F., MacDonald R., Bella A.J., Ansari M.T., Garritty C., Soares-Weiser K., Daniel R., Sampson M., Fox S., Moher D., Wilt T.J. Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and meta-analysis. Ann Intern Med. 2009;151:650-61.